Login to see all of our products!
Products usually ship out within 3-7 business days
The IvyGene test is a blood test that uses advanced DNA sequencing methods to detect the DNA methylation pattern of circulating tumor DNA (ctDNA) in blood samples in order to both confirm the presence of cancer and give quantitative data.
The IvyGene® Score reflects the relative amount of cell-free DNA that contains these methylation markers as a percentage of the total cell-free DNA present. The IvyGene®score is derived from a composite average of methylated vs unmethylated cell-free DNA of specific target sites.
Every day thousands of people in the USA alone are beginning to fight cancer. In 2016, more than 4,600 individuals in the U.S. were diagnosed with cancer daily. The first step to fighting cancer is identifying its presence early, which can be a difficult and frustrating process.
IvyGene is a blood test able to identify the presence of malignant cancer and give quantifiable data about cancer presence.
IvyGene is a liquid biopsy that identifies the presence of malignant cancer in whole blood. A highly accurate and sensitive test, the IvyGene test is a non-invasive tool to aid physicians in identifying malignant cancer presence.
According to studies performed by the National Cancer Institute and American Cancer Society, individuals who identified 25 different types of cancer earlier had a greater chance of survival.
In combination with diagnostic tests, the IvyGene test is another step towards winning the battle with cancer.
IvyGene utilizes ctDNA (circulating tumor DNA) methylation patterns in order to identify the presence of malignant cancer. Methylation occurs when a methyl group (-CH3) is bonded to a Cytosine nucleotide in DNA. By identifying ctDNA methylation patterns, a scientist can compare individual methylation patterns against a known database of methylation patterns, consistent with malignant cancer.
IvyGene is intended to be used in conjunction with other diagnostic and confirmatory tests.
Many DNA tests identify the “propensity to have” or the “likelihood” that cancer will occur. IvyGene identifies actual disease presence.
This site requires cookies in order to provide all of its functionality.